Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings

de Jong, Marion; Valkema, Roelf; Jamar, Francois; Kvols, Larry K.; Kwekkeboom, Dik J.; Breeman, Wout A.P.; Bakker, Willem H.; Smith, Chuck; Pauwels, Stanislas; Krenning, Eric P.

doi:10.1053/snuc.2002.31027

« Previous Next »Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 133-140, April 2002

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings

Marion de Jong
- Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
- Universitaire Catholique Louvain, Brussels, Belgium, USA
- Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
- Address reprint requests to M. de Jong, PhD, Department of Nuclear Medicine, Erasmus University Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Roelf Valkema
- Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
- Universitaire Catholique Louvain, Brussels, Belgium, USA
- Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
Francois Jamar
- Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
- Universitaire Catholique Louvain, Brussels, Belgium, USA
- Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
Larry K. Kvols
- Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
- Universitaire Catholique Louvain, Brussels, Belgium, USA
- Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
Dik J. Kwekkeboom
- Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
- Universitaire Catholique Louvain, Brussels, Belgium, USA
- Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
Wout A.P. Breeman
- Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
- Universitaire Catholique Louvain, Brussels, Belgium, USA
- Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
Willem H. Bakker
- Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
- Universitaire Catholique Louvain, Brussels, Belgium, USA
- Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
Chuck Smith
- Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
- Universitaire Catholique Louvain, Brussels, Belgium, USA
- Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
Stanislas Pauwels
- Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
- Universitaire Catholique Louvain, Brussels, Belgium, USA
- Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
Eric P. Krenning
- Department of Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands, USA
- Universitaire Catholique Louvain, Brussels, Belgium, USA
- Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA